This study is being done to determine if there are differences in mood during the menstrual cycle among women with epilepsy who take various different antiepileptic drugs and women without epilepsy...
Date First Received: January 29, 2008
Last Updated: January 29, 2008
Verified by: Beth Israel Deaconess Medical Center, January 2008
Clinical Trial Phase: N/A | Start Date: November 2007
Overall Status: Recruiting
Estimated Enrollment: 100
Brief Summary
Official Title: “Comparison of Different Antiepileptic Drug Monotherapies for the Occurrence of Premenstrual Dysphoric Disorder Among Women With Epilepsy”
Condition Keyword(s):
This study is being done to determine if there are differences in mood during the menstrual cycle among women with epilepsy who take various different antiepileptic drugs and women without epilepsy.
Study Type: Observational
Study Design: Cohort, Prospective
Study Primary Completion Date: February 2009
Detailed Clinical Trial Description
Participants will be given informed consent during the initial study visit. We will gather information about their seizure disorder and medications and provide them with instructions and a form that they will complete daily for two months (two menstrual cycles). During the third week of each menstrual cycle, they will be asked to return once to provide a blood sample.
Arms, Groups and Cohorts in this Clinical Trial
- : 1
- Lamotrigine Monotherapy
- : 2
- Levetiracetam Monotherapy
- : 3
- Carbamazepine Monotherapy
- : 4
- Phenytoin Monotherapy
- : 5
- Normal control (no epilepsy)
Outcome Measures for this Clinical Trial
Primary Measures
- To determine if the frequency of premenstrual dysphoric disorder differs among antiepileptic drug monotherapies.
- Time Frame: 1 Year
Safety Issue?: No
- Time Frame: 1 Year
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Women with epilepsy, 18-45 years of age. Women will be on one of 4 established (≥ 3 months) AED monotherapies: LTG, CBZ, PHT or LEV and with documented therapeutic range serum AED level during the year prior to enrollment.
- Normal Control women, 18-45 years of age, in good general health by history
Exclusion Criteria:
- Concomitant use of prescribed or OTC reproductive hormones
- Concomitant use of antidepressant and anxiolytic medications such as SSRIs, bupropion, tricyclics, benzodiazepines
Gender Eligibility for this Clinical Trial: Female
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: 45 Years
Are Healthy Volunteers Accepted for this Clinical Trial?: Accepts Healthy Volunteers
Clinical Trial Sponsor Information
Lead Sponsor: Beth Israel Deaconess Medical Center
Overall Clinical Trial Officials and Contacts
Andrew G Herzog, MD Principal Investigator Beth Israel Deaconess Medical Center
Overall Contact: Andrew G Herzog, MD 617 667 4523
Additional Information
Information obtained from ClinicalTrials.gov on September 05, 2008
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00612235
Study ID Number: 2007-P-000357/2
ClinicalTrials.gov Identifier: NCT00612235
Health Authority: United States: Institutional Review Board
Clinical Trials Authorship and Review
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.